Mawer Investment Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-1,280,972
| Closed | -$112M | – | 119 |
|
|
2021
Q4 | $112M | Sell |
1,280,972
-61,100
| -5% | -$5.07M | 0.5% | 38 |
|
|
2021
Q3 | $110M | Sell |
1,342,072
-2,176,642
| -62% | -$196M | 0.53% | 39 |
|
|
2021
Q2 | $321M | Sell |
3,518,714
-1,400,566
| -28% | -$125M | 1.59% | 23 |
|
|
2021
Q1 | $421M | Sell |
4,919,280
-1,706,314
| -26% | -$153M | 2.28% | 16 |
|
|
2020
Q4 | $626M | Sell |
6,625,594
-1,889,797
| -22% | -$165M | 3.69% | 7 |
|
|
2020
Q3 | $740M | Buy |
8,515,391
+570,400
| +7% | +$49.4M | 4.84% | 3 |
|
|
2020
Q2 | $694M | Buy |
7,944,991
+223,664
| +3% | +$19.3M | 5.11% | 3 |
|
|
2020
Q1 | $637M | Buy |
7,721,327
+1,684,503
| +28% | +$150M | 5.86% | 2 |
|
|
2019
Q4 | $572M | Buy |
6,036,824
+46,437
| +0.8% | +$4.17M | 4.63% | 3 |
|
|
2019
Q3 | $521M | Buy |
5,990,387
+176,441
| +3% | +$15.8M | 4.76% | 2 |
|
|
2019
Q2 | $531M | Sell |
5,813,946
-525,663
| -8% | -$44.5M | 3.43% | 2 |
|
|
2019
Q1 | $546M | Buy |
6,339,609
+1,022,443
| +19% | +$82.1M | 3.89% | 2 |
|
|
2018
Q4 | $409M | Buy |
5,317,166
+1,850,369
| +53% | +$144M | 3.39% | 2 |
|
|
2018
Q3 | $268M | Buy |
3,466,797
+154,005
| +5% | +$11.4M | 2.01% | 13 |
|
|
2018
Q2 | $224M | Buy |
3,312,792
+72,746
| +2% | +$5.02M | 1.81% | 16 |
|
|
2018
Q1 | $235M | Buy |
3,240,046
+161,933
| +5% | +$12.3M | 1.97% | 15 |
|
|
2017
Q4 | $232M | Buy |
3,078,113
+103,685
| +3% | +$7.82M | 1.92% | 15 |
|
|
2017
Q3 | $229M | Buy |
2,974,428
+64,876
| +2% | +$4.9M | 1.95% | 16 |
|
|
2017
Q2 | $218M | Sell |
2,909,552
-574,673
| -16% | -$40.7M | 2.01% | 14 |
|
|
2017
Q1 | $232M | Buy |
3,484,225
+98,889
| +3% | +$6.59M | 2.24% | 12 |
|
|
2016
Q4 | $221M | Sell |
3,385,336
-914,935
| -21% | -$59.4M | 2.26% | 13 |
|
|
2016
Q3 | $304M | Buy |
4,300,271
+122,125
| +3% | +$8.9M | 3.19% | 5 |
|
|
2016
Q2 | $309M | Buy |
4,178,146
+392,579
| +10% | +$27.1M | 4.36% | 4 |
|
|
2016
Q1 | $246M | Buy |
3,785,567
+584,228
| +18% | +$39.7M | 2.85% | 5 |
|
|
2015
Q4 | $247M | Buy |
3,201,339
+400,161
| +14% | +$31.8M | 3.17% | 5 |
|
|
2015
Q3 | $231M | Buy |
2,801,178
+422,167
| +18% | +$37.6M | 3.16% | 6 |
|
|
2015
Q2 | $210M | Buy |
2,379,011
+345,439
| +17% | +$31.7M | 2.67% | 8 |
|
|
2015
Q1 | $180M | Buy |
2,033,572
+86,779
| +4% | +$7.7M | 2.29% | 9 |
|
|
2014
Q4 | $162M | Buy |
1,946,793
+87,077
| +5% | +$7.22M | 2.09% | 10 |
|
|
2014
Q3 | $157M | Buy |
1,859,716
+104,808
| +6% | +$8.48M | 2.1% | 10 |
|
|
2014
Q2 | $142M | Sell |
1,754,908
-71,828
| -4% | -$5.65M | 1.89% | 11 |
|
|
2014
Q1 | $139M | Buy |
1,826,736
+164,718
| +10% | +$12M | 1.98% | 12 |
|
|
2013
Q4 | $120M | Buy |
1,662,018
+472,604
| +40% | +$32.9M | 1.75% | 14 |
|
|
2013
Q3 | $81.7M | Buy |
1,189,414
+129,478
| +12% | +$8.57M | 1.31% | 26 |
|
|
2013
Q2 | $67.1M | Buy |
+1,059,936
| New | +$69M | 2.5% | 14 |
|
Other funds holding NVS
Mawer Investment Management's NVS Position: Q1 2022 in Review
Mawer Investment Management sold out of Novartis (NVS) in Q1 2022, closing a stake of 1,280,972 shares — an estimated $112M sold.
Mawer Investment Management first reported a position in NVS in Q2 2013 and held it in 35 quarters. The position peaked at $740M in Q3 2020. 1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2022.
- Mawer Investment Management reported no remaining Novartis position as of Q1 2022 after selling out during the quarter.
- Mawer Investment Management sold 1,280,972 Novartis shares in Q1 2022, an estimated $112M.
- Mawer Investment Management first reported a position in Novartis in Q2 2013 and held it in 35 quarters.
- Mawer Investment Management's Novartis position peaked at $740M in Q3 2020.
- 1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2022.
Based on Mawer Investment Management's 13F filing for Q1 2022, filed 6 May 2022.